Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction
Of the 10 investigated NITs, MAF-5 discriminated best between all conditions except cirrhosis, for which the steatosis-associated fibrosis estimator yielded the highest accuracy. The performance of the fibrosis-4 index was poor, implying that referral pathways for significant liver disease in low-prevalence populations can be improved when more accurate NITs such as MAF-5 are employed.
Authors
- Laurens A. van Kleef (ORCID: https://orcid.org/0000-0002-2333-1182)
- Robert J. de Knegt (ORCID: https://orcid.org/0000-0003-0934-6975)
- Maarten E. Tushuizen (ORCID: https://orcid.org/0000-0001-6342-9056)
- M. Arfan Ikram (ORCID: https://orcid.org/0000-0003-0372-8585)
- Sven Francque (ORCID: https://orcid.org/0000-0002-7527-4714)
- Adriaan Georgius Holleboom (ORCID: https://orcid.org/0000-0002-2911-2917)
- Willem Pieter Brouwer (ORCID: https://orcid.org/0000-0001-8713-1481)
- Jörn M. Schattenberg (ORCID: https://orcid.org/0000-0002-4224-4703)
- Jesse Pustjens
- Manuel Castro Cabezas (ORCID: https://orcid.org/0009-0009-5164-2082)
- Harry L.A. Janssen
Institutions
- University Health Network (CA)
- University of Antwerp (BE)
- Leiden University Medical Center (NL)
- Toronto General Hospital (CA)
- Erasmus MC (NL)
- Sint Franciscus Gasthuis (NL)
- Antwerp University Hospital (BE)
- Saarland University (DE)
Publication Details
- Journal
- Hepatology
- Published
- 2025-05-07
- DOI
- https://doi.org/10.1097/hep.0000000000001356
- Citations
- 7
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 9.48
Funders
- Eli Lilly and Company
- Gilead Sciences
- Amsterdam University Medical Centers
- Fonds Wetenschappelijk Onderzoek
- Eisai
- Novo Nordisk
- European Association for the Study of the Liver
- Vlaamse regering
- Grifols
- Julius Clinical
- Allergan
- HORIZON EUROPE Framework Programme